Form 4: Dyne Therapeutics Director Dirk Kersten Reports Sale of Shares

Director Dirk Kersten reports the sale of Dyne Therapeutics shares under a pre-arranged trading plan.

Summary

• Dirk Kersten, a director of Dyne Therapeutics, reported a transaction involving the sale of 5,441 shares of common stock on October 3, 2024.
• The sale was executed at a weighted average price of $35.13 per share, with individual transactions ranging from $35.00 to $35.39.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ('FCF IV') on April 9, 2024.
• Following the reported transaction, Kersten indirectly beneficially owns 123,323 shares through FCF IV and 5,795,364 shares through ForDyne B.V. ('ForDyne').
• Kersten disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. This filing indicates that a director is selling shares, which could be for a variety of personal financial reasons and doesn't necessarily reflect a negative outlook on the company.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but the existence of a pre-arranged trading plan mitigates concerns about insider information.

Key Dates